Population pharmacokinetic analysis of the IAPs antagonist Debio 1143 and its major metabolite in oncologic patients

Presented at PAGE 2016, Lisbon, Portugal

M. Guidi (1, 2), C. Csajka (1, 2), A. Haouala (3), A. Ménétrey (3) and E. Rouits (3)

1. School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland;
2. Division of Clinical Pharmacology, Department of Laboratories, University Hospital Lausanne, Lausanne, Switzerland;
3. Debiopharm International SA, Lausanne, Switzerland.